Ghiasvand R (2026)
High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma?
Br J Dermatol (in press)
DOI 10.1093/bjd/ljaf523, PubMed 41483011

Unal B, Saatcioglu F (2025)
Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression
Biomark Res, 13 (1), 156
DOI 10.1186/s40364-025-00813-y, PubMed 41372991

Pinto R, Sjurgard IV, Pharo H, Mala T, Vedeld HM, Lind GE (2025)
Molecular stratification of esophageal adenocarcinoma: implications for prognosis and treatment strategy
Oncogene (in press)
DOI 10.1038/s41388-025-03650-3, PubMed 41361079

Kanetsky PA, Almstrup K, Cherlin S, Cortessis VK, Ferlin A, Gietema JA, González-Neira A, Grotmol T, Hamilton RJ, Haugen TB, Kiemeney LA, Kim J, Krausz C, Lessel D, Lothe RA, Nead KT, Nsengimana J, Poynter JN, Rajpert-DeMeyts E, Richiardi L, Schwartz SM, Skotheim RI, Stewart DR, Turnbull C, Wiklund F et al. (2026)
The Testicular Cancer Consortium (TECAC): Filling Knowledge Gaps in the Genetic Etiology of Testicular Germ Cell Tumors
Andrology, e70168 (in press)
DOI 10.1111/andr.70168, PubMed 41486674

Ghiasvand R (2026)
High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma?
Br J Dermatol (in press)
DOI 10.1093/bjd/ljaf523, PubMed 41483011

Kristiansen SK, Shubin K, Zubrienė A, Matulis D, Dernjani N, Juzenas P, Bruland ØS, Juzeniene A (2026)
Radiobiological investigations of a [²¹²Pb]Pb-carbonic anhydrase IX-targeting small-molecule ligand in renal cell carcinoma and colorectal cancer models
Int J Radiat Biol, 1-11 (in press)
DOI 10.1080/09553002.2025.2595630, PubMed 41481374